软肝缩脾丸抗肝纤维化临床和病理学研究

目的观察软肝缩脾丸治疗肝纤维化的临床疗效和安全性。方法将270例患者随机分为两组,治疗组150例,给予软肝缩脾丸治疗;对照组120例,采用大黄蛰虫丸治疗,治疗6个月后评定疗效。结果治疗后治疗组自觉症状改善有效率87.3%,与对照组相比,有显著性差异(P<0.01);两组治疗后肝功能各项指标均较治疗前明显改善(P<0.05或P<0.01),治疗组的改善情况显著优于对照组(P<0.05或P<0.01);两组血清肝纤维化指标治疗前后比较均有明显下降,治疗组优于对照组(P<0.01)。各项肝纤维化指标疗效,治疗组总有效率79.33%,与对照组相比,差异显著(P<0.01);病理学检查治疗组20例,对照组17例,两组治疗后均较治疗前肝脏炎症和肝纤维化程度明显下降,与治疗前相比有显著性差异(P<0.01),治疗后治疗组疗效(总有效率85%)优于对照组(P<0.01)。结论软肝缩脾丸治疗肝纤维化,在改善临床自觉症状、肝功能指标、血清肝纤维化指标和病理组织学等方面疗效确切,治疗过程中未发现不良反应,安全性好。

CLINICAL AND PATHOLOGICAL RESEARCH ON RUANGANSUOPI PILLS IN TREATING HEPATIC FIBROSIS

Objective To observe of clinical effects and safety of ruangansuopi pills.Methods 270 cases were randomly divided into two groups 150 cases in the treatment group were given ruangansuopi pills,while 120 cases in the contrast group were given dahuangzhechong pills.The curative effects were evaluated after 6 months of treatments.Results The subjective symptoms were much more improved in the treatment group than in the contrast group(P<0.01).The indexes of hepatic functions improved in both groups(P<0.05,P<0.01),but there existed significant between the two group(P<0.05,P<0.01).The indexes of hepatic fibrosis declined obviously in both groups,but there existed significant differences between the two groups(P<0.01).The total curative rate in the treatment group was 79.33%(P<0.01).Pathological examinations were conducted in 20 cases from the treatment group and 17 cases from the contrast group.Both groups had good curative effects(P<0.01).The total curative rate in the treatment group was found higher than in the contrast group(P<0.01).Conclusion Ruangansuopi pills can produce good curative results and can be used safely to improve subjective symptoms,hepatic functions,serum hepatic fibrosis and histopathological indexes.